Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies

Infectious Complications in Aggressive B Cell Non-Hodgkin Lymphoma after CD-19 Chimeric Antigen Receptor T Cell Therapy

(2020) Kitsada Wudhikarn et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)

(2020) Deepu Madduri et al.   BLOOD

Infectious Complications Following CD19 Chimeric Antigen Receptor T-cell Therapy for Children, Adolescents, and Young Adults

(2020) Surabhi B Vora et al.   Open Forum Infectious Diseases

Early and late hematologic toxicity following CD19 CAR-T cells

(2019) Shalev Fried et al.   BONE MARROW TRANSPLANTATION

Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma

(2019) Tania Jain et al.   LEUKEMIA

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

(2019) Noopur Raje et al.   NEW ENGLAND JOURNAL OF MEDICINE

Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma

(2019) Jie Xu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy

(2019) Eric L. Smith et al.   Cancer Immunology Research

CD19-DIRECTED CAR T CELL THERAPY (CTL019) FOR RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL AND FOLLICULAR LYMPHOMAS: FOUR YEAR OUTCOMES

(2019) E.A. Chong et al.   HEMATOLOGICAL ONCOLOGY

Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

(2019) Tania Jain et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells

(2019) Ana Cordeiro et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells

(2018) Jae H Park et al.   CLINICAL INFECTIOUS DISEASES

Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector

(2018) Eric L. Smith et al.   MOLECULAR THERAPY

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

(2018) Jae H. Park et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cytokine release syndrome

(2018) Alexander Shimabukuro-Vornhagen et al.   Journal for ImmunoTherapy of Cancer

Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL.

(2018) Jeremy S. Abramson et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Utilization of Chimeric Antigen Receptors T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation

(2018) Ankit J. Kansagra et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells

(2018) Daniel W Lee et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

(2018) Wan-Hong Zhao et al.   Journal of Hematology & Oncology

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

(2018) Frederick L Locke et al.   LANCET ONCOLOGY

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2018) Stephen J. Schuster et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

(2017) Sattva S. Neelapu et al.   Nature Reviews Clinical Oncology

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells

(2017) Juliane Gust et al.   Cancer Discovery

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

(2015) Daniel W Lee et al.   LANCET

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

(2014) M. L. Davila et al.   Science Translational Medicine

CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

(2013) R. J. Brentjens et al.   Science Translational Medicine